Axcella

17 articles with Axcella

• Axcella Health Reports Second Quarter 2019 Financial Results and Provides Company Update

  8/12/2019

  Axcella Health Inc. announced financial results for the second quarter ended June 30, 2019 and provided a company update.

• 

  BioSpace's List of May 2019 Life Science IPOs

  5/23/2019

  A summary of IPOs from companies in the biotech and pharma world since May 1, 2019.
• 

  4 Biotech Companies List on the Nasdaq Today

  5/9/2019

  Four biotech companies began trading on the Nasdaq this morning. Here's a look at today’s launches and one rumored IPO.

• Axcella Announces Patent Issuance for AXA™ Candidate AXA1125 Methods of Use

  4/2/2019

  Patent issuance from Axcella’s broad Endogenous Metabolic Modulator (EMM) portfolio

• 

  BioSpace Movers and Shakers: March 29

  3/29/2019

  Biotech and pharma companies bring on new talent to strengthen leadership teams and boards.

• Axcella to Present Late-Breaker Data on Lead AXA™ Candidate, AXA1665 at EASL, the International Liver Congress™

  3/27/2019

  Axcella Health announced a late-breaker poster presentation for their novel endogenous metabolic modulator composition, AXA1665 in subjects with mild and moderate hepatic insufficiency.

• Axcella Presents Mechanistic Data Demonstrating that AXA1125 Modulated Liver Metabolic, Inflammatory and Fibrotic Pathways

  1/24/2019

  Data further support compositions of Endogenous Metabolic Modulators (EMM) as novel multifactorial assets with the potential to support health or become therapeutically relevant

• Axcella to Present Update at the 37th Annual JP Morgan Healthcare Conference

  1/3/2019

  Axcella Health Inc. (the “Company,” “Axcella,” or “we”), a biotechnology company pioneering a new approach to address metabolic dysregulation and health, today announced that Bill Hinshaw, President and CEO, will present a corporate update at the 37th Annual JP Morgan Healthcare Conference, taking place January 7-10, 2019, at the Westin St. Francis Hotel in San Francisco, CA.

• 

  BioSpace Movers and Shakers Oct. 29

  10/29/2018

  Biopharma companies shore up leadership roles with new hires and appointments, at Axcella Health, Twist Bioscience, and more.

• Axcella to Present New Data at the Annual 2018 AASLD Liver Meeting

  10/22/2018

  Effective therapies for NAFLD require coordinated reprogramming of cellular physiology as multiple pathways drive liver injury and disease progression.

• Axcella Appoints Stephen Mitchener, PharmD, to Senior Vice President, Chief Business Officer

  10/22/2018

  Dr. Mitchener brings 15 years of pharmaceutical industry experience driving domestic and international commercialization, BD&L, operations, and value creation to Axcella.

• 

  Biotech Leadership Transformations: Week of May 28th

  6/3/2018

  There have been a number of leadership changes in the life sciences industries over the past week. BioSpace compiled a roundup of the changing landscape of the c-suite and boards of directors across the industry.

• Axcella Appoints Bill Hinshaw as President and Chief Executive Officer

  5/31/2018

  Mr. Hinshaw is a highly accomplished health care executive with nearly three decades of global pharmaceutical experience and was most recently Executive Vice President and Head of U.S. Oncology at Novartis.

• Axcella Appoints Manu Chakravarthy, M.D., Ph.D., As Chief Medical Officer

  9/14/2017

• Axcella Appoints Tony Tramontin, Ph.D., As Senior Vice President, Chief Scientific Officer

  6/14/2017

• Axcella Announces The Appointment Of Ivana Magovcevic-Liebisch, Ph.D., J.D., As Executive Vice President, Chief Strategy And Corporate Development Officer

  5/11/2017

• Axcella Augments Leadership Team With The Appointment Of Three Key Hires

  1/3/2017